The goal of this research is to find out how safe and effective the new drug Green Memory (GV971-007) is for the treatment of participants with early-stage Alzheimer's (mild cognitive impairment and mild dementia caused by Alzheimer's). We compare the effect of the new drug Green Memory with the effect of a placebo (drug without an active ingredient, a 'fake drug'). The study drug is administered through an IV.
A phase II, double-blind, randomized, placebo-controlled study, parallel-group, multicenter research on the safety and effectiveness of JNJ-63733657. A monoclonal anti-tau-antibody, to be tested with participants in the early stages of Alzheimer’s disease.
Phase IIIb, open-label, multicenter safety study of BIIB037 (aducanumab) in study participants with Alzheimer's disease who previously participated in the aducanumab studies: 221AD103, 221AD301, 221AD302, and 221AD205.
A multicenter, open-label phase II study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of C9orf72 mutations leading to frontotemporal dementia.